Baidu
map

Cochrane DB Syst Rev:急性缺血性卒中后LMWHs抗血栓治疗的“是是非非”

2017-05-02 梁舒瑶 ;常路 环球医学

低分子量肝素(LMWHs)和肝素类似物是比标准普通肝素(UFH)具有更强抗血栓效果的抗凝剂,同时出血并发症风险也较低。2017年4月,发表在《Cochrane Database Syst Rev.》的一篇文章为这些药物的原始Cochrane回顾的更新,该回顾首次发表于2001年,末次更新于2008年。

低分子量肝素(LMWHs)和肝素类似物是比标准普通肝素(UFH)具有更强抗血栓效果的抗凝剂,同时出血并发症风险也较低。2017年4月,发表在《Cochrane Database Syst Rev.》的一篇文章为这些药物的原始Cochrane回顾的更新,该回顾首次发表于2001年,末次更新于2008年。

目的:旨在确定与UFH相比,使用LMWHs或肝素类似物抗血栓治疗是否与死于或依赖于日常生活活动患者比例的降低相关。

主要结果:研究人员纳入了9项试验,涉及3137名参与者。在本更新回顾中,研究人员未纳入任何新的试验。没有研究报道了足够的首要结局细节用于本回顾的分析。总体来说,纳入的研究具有中等的偏倚风险。与UFH相比,没有证据表明LMWH或肝素类似物对治疗期间的全因死亡具有影响(LMWH/肝素类似物组的96/1616人vs UFH组的78/1486人;比值比OR,1.06;95% CI,0.78~1.47;8项试验,3102名参与者,低质量证据)。与UFH相比,LMWH或肝素类似物与深静脉血栓(DVT)的显着性降低相关(OR,0.55;95% CI,0.44~0.70;7项试验,2585名参与者,低质量证据)。但是,诸如肺栓塞(PE)和颅内出血等严重临床事件的数量太少,以至于不能提供可靠的效果估计。

结论:急性缺血性卒中后LMWH或肝素类似物治疗与标准UFH相比,可显着降低DVT发生率,但由于数据太少,不能为其对其他重要结局包括功能结局、死亡和颅内出血的影响提供可靠信息。

多学科讨论记实:

1、肝素类抗凝药的作用靶点与分子量相关:随着分子量的减小,抗 IIa 因子的活性也减低,出血风险越小。

2、过量或出血时可给予鱼精蛋白拮抗 LMWH 的作用。

3、自从静脉肝素出现以来,其在急性缺血性卒中患者中的使用一直存有争议。2016年4月,发表在《Stroke》的一项研究表明,在韩国,静脉肝素用于急性缺血性卒中治疗的频率已经下降,这种变化也许归因于地区性临床实践指南的传播和成功实施。

4、目前指南推荐3~6个月的LMWH单药疗法为癌症相关静脉血栓栓塞(VTE)的一线治疗。但2017年1月,发表在《J Thromb Haemost》的一项研究显示,五分之一癌症相关VTE患者因副作用停止LMWH注射。

5、在2015年3月的《Cochrane Database Syst Rev.》杂志上一篇Cochrane综述评估早期抗凝药物对急性潜在或已证实的缺血卒中患者的有效性和安全性。其结果为早期抗凝治疗与急性缺血性卒中患者的短期或长期预后未存在相关。

原始出处:

Sandercock PA, Leong TS. Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke. Cochrane Database Syst Rev. 2017 Apr 4;4:CD000119. doi: 10.1002/14651858.CD000119.pub4.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1671288, encodeId=987616e1288e7, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sun Apr 15 00:56:00 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892859, encodeId=a4e7189285961, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Mar 11 20:56:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806142, encodeId=a65018061428e, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Mar 03 02:56:00 CST 2018, time=2018-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=201920, encodeId=9d0a20192052, content=感谢分享,谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Wed May 24 07:35:19 CST 2017, time=2017-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193664, encodeId=7efe19366465, content=学习了,值得分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu May 04 11:57:53 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385512, encodeId=09b91385512bf, content=<a href='/topic/show?id=1ea455e6064' target=_blank style='color:#2F92EE;'>#抗血栓治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55760, encryptionId=1ea455e6064, topicName=抗血栓治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef33504, createdName=wsusan1966, createdTime=Thu May 04 07:56:00 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574099, encodeId=5c9215e4099dd, content=<a href='/topic/show?id=ee4955e5730' target=_blank style='color:#2F92EE;'>#抗血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55757, encryptionId=ee4955e5730, topicName=抗血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26516008049, createdName=gwc388, createdTime=Thu May 04 07:56:00 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193266, encodeId=07aa1932664c, content=好内容,值得收集, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Wed May 03 13:01:15 CST 2017, time=2017-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193190, encodeId=7fc8193190c2, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Wed May 03 08:34:42 CST 2017, time=2017-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193180, encodeId=31a5193180d8, content=继续学习中谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Wed May 03 08:26:18 CST 2017, time=2017-05-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1671288, encodeId=987616e1288e7, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sun Apr 15 00:56:00 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892859, encodeId=a4e7189285961, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Mar 11 20:56:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806142, encodeId=a65018061428e, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Mar 03 02:56:00 CST 2018, time=2018-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=201920, encodeId=9d0a20192052, content=感谢分享,谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Wed May 24 07:35:19 CST 2017, time=2017-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193664, encodeId=7efe19366465, content=学习了,值得分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu May 04 11:57:53 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385512, encodeId=09b91385512bf, content=<a href='/topic/show?id=1ea455e6064' target=_blank style='color:#2F92EE;'>#抗血栓治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55760, encryptionId=1ea455e6064, topicName=抗血栓治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef33504, createdName=wsusan1966, createdTime=Thu May 04 07:56:00 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574099, encodeId=5c9215e4099dd, content=<a href='/topic/show?id=ee4955e5730' target=_blank style='color:#2F92EE;'>#抗血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55757, encryptionId=ee4955e5730, topicName=抗血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26516008049, createdName=gwc388, createdTime=Thu May 04 07:56:00 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193266, encodeId=07aa1932664c, content=好内容,值得收集, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Wed May 03 13:01:15 CST 2017, time=2017-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193190, encodeId=7fc8193190c2, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Wed May 03 08:34:42 CST 2017, time=2017-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193180, encodeId=31a5193180d8, content=继续学习中谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Wed May 03 08:26:18 CST 2017, time=2017-05-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1671288, encodeId=987616e1288e7, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sun Apr 15 00:56:00 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892859, encodeId=a4e7189285961, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Mar 11 20:56:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806142, encodeId=a65018061428e, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Mar 03 02:56:00 CST 2018, time=2018-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=201920, encodeId=9d0a20192052, content=感谢分享,谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Wed May 24 07:35:19 CST 2017, time=2017-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193664, encodeId=7efe19366465, content=学习了,值得分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu May 04 11:57:53 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385512, encodeId=09b91385512bf, content=<a href='/topic/show?id=1ea455e6064' target=_blank style='color:#2F92EE;'>#抗血栓治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55760, encryptionId=1ea455e6064, topicName=抗血栓治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef33504, createdName=wsusan1966, createdTime=Thu May 04 07:56:00 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574099, encodeId=5c9215e4099dd, content=<a href='/topic/show?id=ee4955e5730' target=_blank style='color:#2F92EE;'>#抗血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55757, encryptionId=ee4955e5730, topicName=抗血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26516008049, createdName=gwc388, createdTime=Thu May 04 07:56:00 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193266, encodeId=07aa1932664c, content=好内容,值得收集, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Wed May 03 13:01:15 CST 2017, time=2017-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193190, encodeId=7fc8193190c2, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Wed May 03 08:34:42 CST 2017, time=2017-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193180, encodeId=31a5193180d8, content=继续学习中谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Wed May 03 08:26:18 CST 2017, time=2017-05-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1671288, encodeId=987616e1288e7, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sun Apr 15 00:56:00 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892859, encodeId=a4e7189285961, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Mar 11 20:56:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806142, encodeId=a65018061428e, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Mar 03 02:56:00 CST 2018, time=2018-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=201920, encodeId=9d0a20192052, content=感谢分享,谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Wed May 24 07:35:19 CST 2017, time=2017-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193664, encodeId=7efe19366465, content=学习了,值得分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu May 04 11:57:53 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385512, encodeId=09b91385512bf, content=<a href='/topic/show?id=1ea455e6064' target=_blank style='color:#2F92EE;'>#抗血栓治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55760, encryptionId=1ea455e6064, topicName=抗血栓治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef33504, createdName=wsusan1966, createdTime=Thu May 04 07:56:00 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574099, encodeId=5c9215e4099dd, content=<a href='/topic/show?id=ee4955e5730' target=_blank style='color:#2F92EE;'>#抗血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55757, encryptionId=ee4955e5730, topicName=抗血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26516008049, createdName=gwc388, createdTime=Thu May 04 07:56:00 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193266, encodeId=07aa1932664c, content=好内容,值得收集, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Wed May 03 13:01:15 CST 2017, time=2017-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193190, encodeId=7fc8193190c2, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Wed May 03 08:34:42 CST 2017, time=2017-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193180, encodeId=31a5193180d8, content=继续学习中谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Wed May 03 08:26:18 CST 2017, time=2017-05-03, status=1, ipAttribution=)]
    2017-05-24 lofter

    感谢分享,谢谢!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1671288, encodeId=987616e1288e7, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sun Apr 15 00:56:00 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892859, encodeId=a4e7189285961, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Mar 11 20:56:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806142, encodeId=a65018061428e, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Mar 03 02:56:00 CST 2018, time=2018-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=201920, encodeId=9d0a20192052, content=感谢分享,谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Wed May 24 07:35:19 CST 2017, time=2017-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193664, encodeId=7efe19366465, content=学习了,值得分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu May 04 11:57:53 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385512, encodeId=09b91385512bf, content=<a href='/topic/show?id=1ea455e6064' target=_blank style='color:#2F92EE;'>#抗血栓治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55760, encryptionId=1ea455e6064, topicName=抗血栓治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef33504, createdName=wsusan1966, createdTime=Thu May 04 07:56:00 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574099, encodeId=5c9215e4099dd, content=<a href='/topic/show?id=ee4955e5730' target=_blank style='color:#2F92EE;'>#抗血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55757, encryptionId=ee4955e5730, topicName=抗血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26516008049, createdName=gwc388, createdTime=Thu May 04 07:56:00 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193266, encodeId=07aa1932664c, content=好内容,值得收集, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Wed May 03 13:01:15 CST 2017, time=2017-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193190, encodeId=7fc8193190c2, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Wed May 03 08:34:42 CST 2017, time=2017-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193180, encodeId=31a5193180d8, content=继续学习中谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Wed May 03 08:26:18 CST 2017, time=2017-05-03, status=1, ipAttribution=)]
    2017-05-04 1ddf0692m34(暂无匿称)

    学习了,值得分享

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1671288, encodeId=987616e1288e7, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sun Apr 15 00:56:00 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892859, encodeId=a4e7189285961, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Mar 11 20:56:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806142, encodeId=a65018061428e, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Mar 03 02:56:00 CST 2018, time=2018-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=201920, encodeId=9d0a20192052, content=感谢分享,谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Wed May 24 07:35:19 CST 2017, time=2017-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193664, encodeId=7efe19366465, content=学习了,值得分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu May 04 11:57:53 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385512, encodeId=09b91385512bf, content=<a href='/topic/show?id=1ea455e6064' target=_blank style='color:#2F92EE;'>#抗血栓治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55760, encryptionId=1ea455e6064, topicName=抗血栓治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef33504, createdName=wsusan1966, createdTime=Thu May 04 07:56:00 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574099, encodeId=5c9215e4099dd, content=<a href='/topic/show?id=ee4955e5730' target=_blank style='color:#2F92EE;'>#抗血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55757, encryptionId=ee4955e5730, topicName=抗血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26516008049, createdName=gwc388, createdTime=Thu May 04 07:56:00 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193266, encodeId=07aa1932664c, content=好内容,值得收集, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Wed May 03 13:01:15 CST 2017, time=2017-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193190, encodeId=7fc8193190c2, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Wed May 03 08:34:42 CST 2017, time=2017-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193180, encodeId=31a5193180d8, content=继续学习中谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Wed May 03 08:26:18 CST 2017, time=2017-05-03, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1671288, encodeId=987616e1288e7, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sun Apr 15 00:56:00 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892859, encodeId=a4e7189285961, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Mar 11 20:56:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806142, encodeId=a65018061428e, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Mar 03 02:56:00 CST 2018, time=2018-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=201920, encodeId=9d0a20192052, content=感谢分享,谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Wed May 24 07:35:19 CST 2017, time=2017-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193664, encodeId=7efe19366465, content=学习了,值得分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu May 04 11:57:53 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385512, encodeId=09b91385512bf, content=<a href='/topic/show?id=1ea455e6064' target=_blank style='color:#2F92EE;'>#抗血栓治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55760, encryptionId=1ea455e6064, topicName=抗血栓治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef33504, createdName=wsusan1966, createdTime=Thu May 04 07:56:00 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574099, encodeId=5c9215e4099dd, content=<a href='/topic/show?id=ee4955e5730' target=_blank style='color:#2F92EE;'>#抗血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55757, encryptionId=ee4955e5730, topicName=抗血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26516008049, createdName=gwc388, createdTime=Thu May 04 07:56:00 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193266, encodeId=07aa1932664c, content=好内容,值得收集, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Wed May 03 13:01:15 CST 2017, time=2017-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193190, encodeId=7fc8193190c2, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Wed May 03 08:34:42 CST 2017, time=2017-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193180, encodeId=31a5193180d8, content=继续学习中谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Wed May 03 08:26:18 CST 2017, time=2017-05-03, status=1, ipAttribution=)]
    2017-05-04 gwc388
  8. [GetPortalCommentsPageByObjectIdResponse(id=1671288, encodeId=987616e1288e7, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sun Apr 15 00:56:00 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892859, encodeId=a4e7189285961, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Mar 11 20:56:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806142, encodeId=a65018061428e, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Mar 03 02:56:00 CST 2018, time=2018-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=201920, encodeId=9d0a20192052, content=感谢分享,谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Wed May 24 07:35:19 CST 2017, time=2017-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193664, encodeId=7efe19366465, content=学习了,值得分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu May 04 11:57:53 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385512, encodeId=09b91385512bf, content=<a href='/topic/show?id=1ea455e6064' target=_blank style='color:#2F92EE;'>#抗血栓治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55760, encryptionId=1ea455e6064, topicName=抗血栓治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef33504, createdName=wsusan1966, createdTime=Thu May 04 07:56:00 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574099, encodeId=5c9215e4099dd, content=<a href='/topic/show?id=ee4955e5730' target=_blank style='color:#2F92EE;'>#抗血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55757, encryptionId=ee4955e5730, topicName=抗血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26516008049, createdName=gwc388, createdTime=Thu May 04 07:56:00 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193266, encodeId=07aa1932664c, content=好内容,值得收集, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Wed May 03 13:01:15 CST 2017, time=2017-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193190, encodeId=7fc8193190c2, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Wed May 03 08:34:42 CST 2017, time=2017-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193180, encodeId=31a5193180d8, content=继续学习中谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Wed May 03 08:26:18 CST 2017, time=2017-05-03, status=1, ipAttribution=)]
    2017-05-03 杨利洪

    好内容,值得收集

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1671288, encodeId=987616e1288e7, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sun Apr 15 00:56:00 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892859, encodeId=a4e7189285961, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Mar 11 20:56:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806142, encodeId=a65018061428e, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Mar 03 02:56:00 CST 2018, time=2018-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=201920, encodeId=9d0a20192052, content=感谢分享,谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Wed May 24 07:35:19 CST 2017, time=2017-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193664, encodeId=7efe19366465, content=学习了,值得分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu May 04 11:57:53 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385512, encodeId=09b91385512bf, content=<a href='/topic/show?id=1ea455e6064' target=_blank style='color:#2F92EE;'>#抗血栓治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55760, encryptionId=1ea455e6064, topicName=抗血栓治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef33504, createdName=wsusan1966, createdTime=Thu May 04 07:56:00 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574099, encodeId=5c9215e4099dd, content=<a href='/topic/show?id=ee4955e5730' target=_blank style='color:#2F92EE;'>#抗血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55757, encryptionId=ee4955e5730, topicName=抗血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26516008049, createdName=gwc388, createdTime=Thu May 04 07:56:00 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193266, encodeId=07aa1932664c, content=好内容,值得收集, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Wed May 03 13:01:15 CST 2017, time=2017-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193190, encodeId=7fc8193190c2, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Wed May 03 08:34:42 CST 2017, time=2017-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193180, encodeId=31a5193180d8, content=继续学习中谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Wed May 03 08:26:18 CST 2017, time=2017-05-03, status=1, ipAttribution=)]
    2017-05-03 dhzzm

    学习了分享了

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1671288, encodeId=987616e1288e7, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sun Apr 15 00:56:00 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892859, encodeId=a4e7189285961, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Mar 11 20:56:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806142, encodeId=a65018061428e, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Mar 03 02:56:00 CST 2018, time=2018-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=201920, encodeId=9d0a20192052, content=感谢分享,谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Wed May 24 07:35:19 CST 2017, time=2017-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193664, encodeId=7efe19366465, content=学习了,值得分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu May 04 11:57:53 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385512, encodeId=09b91385512bf, content=<a href='/topic/show?id=1ea455e6064' target=_blank style='color:#2F92EE;'>#抗血栓治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55760, encryptionId=1ea455e6064, topicName=抗血栓治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef33504, createdName=wsusan1966, createdTime=Thu May 04 07:56:00 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574099, encodeId=5c9215e4099dd, content=<a href='/topic/show?id=ee4955e5730' target=_blank style='color:#2F92EE;'>#抗血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55757, encryptionId=ee4955e5730, topicName=抗血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26516008049, createdName=gwc388, createdTime=Thu May 04 07:56:00 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193266, encodeId=07aa1932664c, content=好内容,值得收集, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Wed May 03 13:01:15 CST 2017, time=2017-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193190, encodeId=7fc8193190c2, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Wed May 03 08:34:42 CST 2017, time=2017-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193180, encodeId=31a5193180d8, content=继续学习中谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Wed May 03 08:26:18 CST 2017, time=2017-05-03, status=1, ipAttribution=)]
    2017-05-03 往日如昨

    继续学习中谢谢

    0

相关资讯

Stroke:CT灌注成像可用来筛选卒中患者的血管内治疗

背景:可应用不同的影响学检查评估卒中患者是否进行血管内治疗。研究者试图确定与CT平扫相比, CT灌注成像(CTP)是否可改善血管内治疗的预后。方法: 前瞻性收集登记记录在2010年9月到2016年3月期间的前循环卒中患者,这些患者在三级医院行支架血栓取栓术。将选择CTP的患者与CT平扫的患者相比。主要终点是90天的改良Rankin量表(mRS)。结果:共纳入602例患者。选择CTP的患者(n =

Stroke:eGFR降低的高血压和非高血压患者卒中预后如何?

由此可见,降低的eGFR对全因死亡率和复发性卒中的影响在高血压患者中并不显著,并与高血压患者有所差异,但降低eGFR的无高血压患者比那些患有高血压的患者发生脑卒中相关残疾的风险更高。

Stroke:亚洲房颤患者用CHA2DS2-VASc评分进行卒中危险分层性能如何?

由此可见,亚洲人中CHA2DS2-VASc评分的性能与西方人群相当。该评分在定义真正的卒中/血栓栓塞低风险AF患者上表现出了良好的性能。

Stroke:针灸能预防卒中后抑郁吗?

由此可见,住院脑卒中患者出院后3个月内针灸治疗与抑郁发生率无相关性。

Cochrane Database Syst Rev:急性缺血性卒中后LMWHs抗血栓治疗的“是是非非”

低分子量肝素(LMWHs)和肝素类似物是比标准普通肝素(UFH)具有更强抗血栓效果的抗凝剂,同时出血并发症风险也较低。2017年4月,发表在《Cochrane Database Syst Rev.》的一篇文章为这些药物的原始Cochrane回顾的更新,该回顾首次发表于2001年,末次更新于2008年。

J Alzheimers Dis:白质高信号可预测卒中后认知功能

背景:白质高信号(WMH)可用于预测卒中或短暂性脑缺血发作(TIA)后认知能力下降。然而,WMH只是一个脑小血管疾病(SVD)的影像学指标。目的:本研究的目的是确定增加其他SVD指标是否改善卒中后认知功能的预测。方法:纳入特拉维夫的急性脑卒中患者队列(TABASCO)中首发卒中或TIA的患者266例。卒中发病后七天内进行MRI扫描。研究者评估卒中后一年的认知性能与总SVD负担评分的相关性,包括WM

Baidu
map
Baidu
map
Baidu
map